Your session is about to expire
What is Jynarque
TolvaptanThe Generic name of this drug
Treatment SummaryTolvaptan is a medication used to treat low sodium levels in the blood. This condition is called hyponatremia, and it can be caused by heart failure, liver disease, or a hormone imbalance. Tolvaptan was approved by the FDA in 2009.
Samscais the brand name
Jynarque Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Samsca
Tolvaptan
2009
20
Approved as Treatment by the FDA
Tolvaptan, also called Samsca, is approved by the FDA for 3 uses including symptomatic hypervolemic Hyponatremia and Polycystic Kidney, Autosomal Dominant .symptomatic hypervolemic Hyponatremia
Polycystic Kidney, Autosomal Dominant
Helps manage Autosomal Dominant Polycystic Kidney Disease （ADPKD)
symptomatic euvolemic Hyponatremia
Effectiveness
How Jynarque Affects PatientsTaking tolvaptan leads to an increase in the amount of urine and fluids consumed, resulting in a loss of fluids from the body. This drug increases the levels of sodium and osmolality in the blood 4-8 hours after use, and these effects last up to 24 hours. As the dosage increases, so do the changes in sodium and osmolality levels. Additionally, 4 hours after taking tolvaptan, urine osmolality decreases and free water clearance increases. Tolvaptan binds to V2 receptors in the body 29 times more than it binds to V1a receptors, and does not bind
How Jynarque works in the bodyTolvaptan is a medication that blocks the action of a hormone called vasopressin. When vasopressin binds to certain receptor cells in the body, it causes cells in the kidneys to absorb more water. Tolvaptan prevents this process from happening, increasing urine volume and reducing intravascular volume. This is especially helpful for heart failure patients, who tend to have higher levels of vasopressin.
When to interrupt dosage
The suggested dose of Jynarque is contingent upon the diagnosed circumstance, such as symptomatic hypervolemic Hyponatremia, symptomatic euvolemic Hyponatremia and Polycystic Kidney, Autosomal Dominant. The magnitude of dosage is dependent upon the method of administration provided in the table below.Condition
Dosage
Administration
symptomatic hypervolemic Hyponatremia
, 15.0 mg, 30.0 mg, 60.0 mg, 90.0 mg, 120.0 mg, 45.0 mg, 7.5 mg
Tablet - Oral, , Tablet, Oral
Polycystic Kidney, Autosomal Dominant
, 15.0 mg, 30.0 mg, 60.0 mg, 90.0 mg, 120.0 mg, 45.0 mg, 7.5 mg
Tablet - Oral, , Tablet, Oral
symptomatic euvolemic Hyponatremia
, 15.0 mg, 30.0 mg, 60.0 mg, 90.0 mg, 120.0 mg, 45.0 mg, 7.5 mg
Tablet - Oral, , Tablet, Oral
Warnings
There are 20 known major drug interactions with Jynarque.Common Jynarque Drug Interactions
Drug Name
Risk Level
Description
Desmopressin
Major
The therapeutic efficacy of Desmopressin can be decreased when used in combination with Tolvaptan.
Agmatine
Minor
The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Agmatine.
Aliskiren
Minor
The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Aliskiren.
Alminoprofen
Minor
The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Alminoprofen.
Anisodamine
Minor
The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Anisodamine.
Jynarque Toxicity & Overdose RiskThe lowest toxic dose of tolvaptan in rats and dogs is greater than 2000mg/kg. Common side effects of tolvaptan are feeling thirsty, dry mouth, weakness, constipation, increased urination, and high blood sugar.
Jynarque Novel Uses: Which Conditions Have a Clinical Trial Featuring Jynarque?
Currently, 6 active trials are exploring the utility of Jynarque in providing symptomatic relief for euvolemic Hyponatremia, Polycystic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease and symptomatic hypervolemic Hyponatremia.Condition
Clinical Trials
Trial Phases
symptomatic euvolemic Hyponatremia
0 Actively Recruiting
Polycystic Kidney, Autosomal Dominant
4 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 3
symptomatic hypervolemic Hyponatremia
0 Actively Recruiting
Jynarque Reviews: What are patients saying about Jynarque?
5Patient Review
8/1/2022 Jynarque has been working great for me. I'm proof that different people can get different results from the same treatment; my kidneys have actually been getting better lately.
1.7Patient Review
11/27/2019 It's hard to tell if this treatment is effective because the amount of time it requires is so significant. Additionally, the protocol and requirements are very demanding, and my doctor's office has had trouble keeping up with the blood testing schedule. The insurance company is also less than helpful when things go wrong. Overall, I would not recommend this treatment.
Patient Q&A Section about jynarque
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.How effective is Jynarque?
"The relative rate of events related to ADPKD decreased by 13.5% with JYNARQUE. This was driven by effects on worsening kidney function and pain events. In contrast, tolvaptan had no effect on progression of either hypertension or albuminuria."
Answered by AI
What is Jynarque used for?
"This medication is used by those who have autosomal dominant polycystic kidney disease. This disease leads to the growth of fluid-filled sacs, known as cysts, in the kidneys."
Answered by AI
How long do you take Jynarque?
"If you take JYNARQUE® (tolvaptan), it could seriously injure your liver or even kill you. Check with your doctor before starting this medication, and then again 2 and 4 weeks after you start. After that, you should have checkups monthly for 18 months, and then every 3 months after that."
Answered by AI